Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …

Minimizing exposure of the fetus to medication and reducing adverse off-target effects in the
mother are the primary challenges in developing novel drugs to treat pregnancy …

Rationale: The availability of therapeutics to treat pregnancy complications is severely
lacking, mainly due to the risk of harm to the fetus. In placental malaria, Plasmodium …

The biomedical use of nanoparticles (NPs) has been the focus of intense research for over a
decade. As most NPs are explored as carriers to alter the biodistribution, pharmacokinetics …

In areas of endemicity pregnancy-associated malaria is an important cause of maternal
anemia, stillbirth, and delivery of low-birth-weight children. The syndrome is precipitated by …

Abstract The Developmental Origins of Health and Disease (DOHaD) theory states that a
sub-optimal prenatal and early postnatal environment during development leads to an …

Two vaccines based on Plasmodium falciparum protein VAR2CSA are currently in clinical
evaluation to prevent placental malaria (PM), but a deeper understanding of var2csa …

There is substantial immuno-epidemiological evidence that the parasite-encoded, so-called
variant surface antigens (VSAs) such as PfEMP1 on the surface of infected erythrocytes (IEs) …

Gestational trophoblastic neoplasia (GTN) can result from the over-proliferation of
trophoblasts. Treatment of choriocarcinoma, the most aggressive GTN, currently requires …

Acquired protection from Plasmodium falciparum placental malaria, a major cause of
maternal, fetal, and infant morbidity, is mediated by IgG specific for the P. falciparum …